Russell Frank Company’s Myriad Genetics MYGN Stock Holding History

Russell Frank Company’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$29.5M	Buy	788,631 +96,463	+14%	+$3.63M	0.05%	421
2015 Q4	$30.4M	Buy	692,168 +679,788	+5,491%	+$28.7M	0.05%	390
2015 Q3	$464K	Buy	12,380 +6,214	+101%	+$221K	﹤0.01%	2491
2015 Q2	$210K	Buy	6,166 +4,649	+306%	+$158K	﹤0.01%	2796
2015 Q1	$54K	Sell	1,517 -115,532	-99%	-$4.14M	﹤0.01%	2801
2014 Q4	$4.08M	Sell	117,049 -29,965	-20%	-$1.06M	0.01%	1411
2014 Q3	$5.67M	Sell	147,014 -112,613	-43%	-$4.2M	0.01%	1203
2014 Q2	$10.1M	Sell	259,627 -57,634	-18%	-$2.14M	0.02%	913
2014 Q1	$12.6M	Sell	317,261 -29,383	-8%	-$910K	0.02%	758
2013 Q4	$9.16M	Buy	346,644 +121,927	+54%	+$3.08M	0.02%	901
2013 Q3	$5.82M	Buy	224,717 +27,026	+14%	+$768K	0.01%	1235
2013 Q2	$5.31M	Buy	+197,691	New	+$5.73M	0.01%	1204

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Russell Frank Company's MYGN Position: Q1 2016 in Review

Russell Frank Company increased its Myriad Genetics (MYGN) stake by 14% in Q1 2016, buying an estimated $3.63M and bringing the position to 788,631 shares worth $29.5M. The position accounts for 0.05% of the portfolio, ranked #421.

Russell Frank Company first reported a position in MYGN in Q2 2013 and has held it in 12 quarters since. The position peaked at $30.4M in Q4 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

Russell Frank Company held 788,631 shares of Myriad Genetics worth $29.5M as of Q1 2016.
Russell Frank Company bought 96,463 Myriad Genetics shares in Q1 2016, an estimated $3.63M.
Myriad Genetics made up 0.05% of Russell Frank Company's portfolio in Q1 2016, its #421 holding.
Russell Frank Company first reported a position in Myriad Genetics in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's Myriad Genetics position peaked at $30.4M in Q4 2015.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.